Daniel Park

Dr. Daniel Park


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KKKyung-il John Kim
Kyung-il John Kim
HZHannah Zhong
Hannah Zhong
DTDerek Tai
Derek Tai
PSPranati Shah
Pranati Shah
DPDaniel Park
Daniel Park
DCDani Ran Castillo
Dani Ran Castillo
Gastric cancer (GC), frequently diagnosed at advanced/metastatic stages, necessitates the identification of novel biomarkers for early detection and optimized treatment strategies. Emerging research suggests a strong association between gut microbiome alterations and GC development, progression, and therapeutic response. This study explores the potential of the gastric microbiome as a source of biomarkers to predict GC prognosis and progression, while also assessing its modulatory influence on first-line treatments for metastatic disease. Beyond Helicobacter pylori, other bacterial taxa such as Fusobacterium, Lactobacillus, and Peptostreptococcus have been implicated in carcinogenesis and immune modulation. Microbial dysbiosis is increasingly linked to chronic inflammation, immune evasion, and altered drug metabolism, which may influence tumor dynamics and therapeutic outcomes. Microbiome-based biomarkers offer promising avenues for early GC detection, particularly in H. pylori-negative cases, and may enhance response prediction to immunotherapies, including PD-1/PD-L1 inhibitors. However, critical challenges remain, including a lack of methodological standardization, confounding variables like diet and antibiotic use, and unresolved issues around causation versus correlation. Despite these hurdles, the integration of microbiome data with other omics platforms (e.g., transcriptomics, metabolomics, ctDNA) holds significant promise for refining predictive models. Furthermore, therapeutic modulation of the microbiome, via probiotics, fecal microbiota transplantation, or diet may offer novel strategies to enhance treatment efficacy and reduce toxicity in GC management.